Latest News

Date Title Topic
19 Jul 2017 FDA Approves Neratinib for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
18 Jul 2017 Patient Guide in Glioma Now Available Also in Dutch
18 Jul 2017 FDA ODAC Recommends Biosimilar Bevacizumab and Trastuzumab Anticancer agents & Biologic therapy
17 Jul 2017 Patient Guide in Bone Sarcoma Now Available Also in Dutch
17 Jul 2017 FDA Grants Priority Review for Abemaciclib in Advanced Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
14 Jul 2017 Clinical Practice Guidelines
14 Jul 2017 FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy Palliative and supportive care
13 Jul 2017 A decade after completion of the HERA trial: where are we in the adjuvant treatment of patients with HER2-positive early breast cancer? Breast cancer
13 Jul 2017 The EU-Funded MiRoR Project Will Transform Clinical Research Practice and Increase its Value Bioethics, legal and economic issues
12 Jul 2017 NICE Terminates Appraisals for Daratumumab with Lenalidomide and Dexamethasone, Bortezomib in Relapsed Multiple Myeloma, and Ibrutinib for Untreated CLL Haematologic malignancies - Anticancer agents & Biologic therapy
11 Jul 2017 FDA Approves L-Glutamine Powder for the Treatment of Sickle Cell Disease Cancer in Special Situations - Haematologic malignancies
10 Jul 2017 First-Line Nivolumab in Stage IV or Recurrent NSCLC with a PD-L1 Expression Level of 5% or More Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
07 Jul 2017 FDA Grants Marketing Approval to the Praxis Extended RAS Panel Personalised medicine - Anticancer agents & Biologic therapy
06 Jul 2017 NICE Develops a Medtech Innovation Briefing on L-Dex U400 for Lymphoedema After Breast Cancer Treatment Breast cancer - Diagnosis, Imaging and Staging
05 Jul 2017 Metastatic Colorectal Cancer: Beyond RAS and BRAF Translational research - Gastrointestinal cancers